Livzon Pharmaceutical Group 미래 성장

Future 기준 확인 1/6

Livzon Pharmaceutical Group (는) 각각 연간 10.2% 및 5.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.1% 로 예상됩니다.

주요 정보

10.2%

수익 성장률

10.0%

EPS 성장률

Pharmaceuticals 수익 성장	18.8%
매출 성장률	5.6%
향후 자기자본 수익률	16.1%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2024

최근 미래 성장 업데이트

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Recent updates

Livzon Pharmaceutical Group (SZSE:000513) Has A Rock Solid Balance Sheet

Dec 24

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Aug 30

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Aug 09

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Jul 02

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

수익 및 매출 성장 예측

SZSE:000513 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	13,478	2,529	N/A	3,746	6
12/31/2025	12,656	2,274	N/A	2,064	7
12/31/2024	12,073	2,052	N/A	4,563	7
9/30/2024	11,857	2,025	2,673	3,344	N/A
6/30/2024	12,022	1,990	2,860	3,552	N/A
3/31/2024	12,260	1,980	3,044	3,873	N/A
12/31/2023	12,430	1,954	2,428	3,249	N/A
9/30/2023	12,796	2,004	2,433	3,137	N/A
6/30/2023	13,017	2,026	1,827	2,574	N/A
3/31/2023	12,564	1,938	1,477	2,362	N/A
12/31/2022	12,630	1,909	1,833	2,773	N/A
9/30/2022	12,183	1,830	1,152	2,445	N/A
6/30/2022	12,131	1,731	1,236	2,654	N/A
3/31/2022	12,193	1,809	833	2,098	N/A
1/1/2022	12,064	1,776	593	1,902	N/A
9/30/2021	11,964	1,746	905	1,948	N/A
6/30/2021	11,661	1,773	1,036	1,962	N/A
3/31/2021	11,365	1,835	1,507	2,313	N/A
1/1/2021	10,520	1,715	1,514	2,161	N/A
9/30/2020	10,015	1,685	1,342	1,857	N/A
6/30/2020	9,541	1,569	1,272	1,682	N/A
3/31/2020	9,282	1,309	1,236	1,649	N/A
1/1/2020	9,385	1,303	1,369	1,767	N/A
9/30/2019	9,314	1,182	1,685	2,069	N/A
6/30/2019	9,235	1,188	1,830	2,244	N/A
3/31/2019	9,099	1,128	1,131	1,540	N/A
12/31/2018	8,861	1,082	793	1,268	N/A
9/30/2018	8,851	1,123	531	1,015	N/A
6/30/2018	8,821	4,558	N/A	850	N/A
3/31/2018	8,774	4,501	N/A	1,266	N/A
1/1/2018	8,531	4,429	N/A	1,316	N/A
9/30/2017	8,450	4,416	N/A	1,324	N/A
6/30/2017	8,142	879	N/A	1,419	N/A
3/31/2017	8,032	829	N/A	1,399	N/A
12/31/2016	7,652	784	N/A	1,279	N/A
9/30/2016	7,458	742	N/A	1,240	N/A
6/30/2016	7,289	691	N/A	1,002	N/A
3/31/2016	6,813	670	N/A	990	N/A
12/31/2015	6,621	623	N/A	928	N/A
9/30/2015	6,311	588	N/A	894	N/A
6/30/2015	6,031	566	N/A	748	N/A
3/31/2015	5,869	555	N/A	623	N/A
12/31/2014	5,544	516	N/A	717	N/A
9/30/2014	5,506	532	N/A	482	N/A
6/30/2014	5,085	519	N/A	458	N/A
3/31/2014	4,791	484	N/A	561	N/A
12/31/2013	4,619	488	N/A	440	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 000513 의 연간 예상 수익 증가율( 10.2% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 000513 의 연간 수익( 10.2% ) CN 시장( 25.5% 보다 느리게 성장할 것으로 예상됩니다. 25.5% 연간).

고성장 수익: 000513 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 000513 의 수익(연간 5.6% ) CN 시장( 13.7% 보다 느리게 성장할 것으로 예상됩니다. 13.7% 연간).

고성장 수익: 000513 의 수익(연간 5.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 000513 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 16.1 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/30 18:47
장 마감 주가	2024/12/30 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Livzon Pharmaceutical Group Inc. 28 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ling Zhang	BNP Paribas Securities (Asia)
Helena Qiu	CCB International Securities Limited
Shuchang Liu	Changjiang Securities Co. LTD.

Livzon Pharmaceutical Group 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased to CN¥42.19

Price target raised to CN¥51.22

Recent updates

Livzon Pharmaceutical Group (SZSE:000513) Has A Rock Solid Balance Sheet

Livzon Pharmaceutical Group Inc. Announces Election of Lin Nanqi as Non-Executive Director

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Now 21% undervalued after recent price drop

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥1.35

Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34